Novel Treatment For Relapsing Lyme, Babesia, and Bartonella

October 2, 2023

https://www.mdpi.com/2076-2607/11/9/2301

Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections

by 1,2,*, 2 and Phyllis R. Freeman2
Microorganisms 2023, 11(9), 2301; https://doi.org/10.3390/microorganisms11092301
Received: 8 August 2023 / Revised: 27 August 2023 / Accepted: 8 September 2023 / Published: 12 September 2023
(This article belongs to the Special Issue Bartonella and Bartonellosis: New Advances and Further Challenges)

Abstract

Twenty-five patients with relapsing and remitting Borreliosis, Babesiosis, and bartonellosis despite extended anti-infective therapy were prescribed double-dose dapsone combination therapy (DDDCT), followed by one or several courses of High Dose Dapsone Combination Therapy (HDDCT). A retrospective chart review of these 25 patients undergoing DDDCT therapy and HDDCT demonstrated that 100% improved their tick-borne symptoms, and patients completing 6–7 day pulses of HDDCT had superior levels of improvement versus 4-day pulses if Bartonella was present.
At the completion of treatment, 7/23 (30.5%) who completed 8 weeks of DDDCT followed by a 5–7 day pulse of HDDCT remained in remission for 3–9 months, and 3/23 patients (13%) who recently finished treatment were 1 ½ months in full remission.
In conclusion, DDDCT followed by 6–7 day pulses of HDDCT could represent a novel, effective anti-infective strategy in chronic Lyme disease/Post Treatment Lyme Disease Syndrome (PTLDS) and associated co-infections, including Bartonella, especially in individuals who have failed standard antibiotic protocols.
_____________
For more:

Category:

Babesia, Bartonella, Lyme, research, Treatment

Comments Off on Novel Treatment For Relapsing Lyme, Babesia, and Bartonella